6
Views
2
CrossRef citations to date
0
Altmetric
Articles

Anti-vascular cell adhesion molecule-1 and anti-very late antigen-4 monoclonal antibodies inhibit neointimal hyperplasia in the murine model of arterial injury

, &
Pages 147-152 | Received 15 Dec 2003, Accepted 01 Aug 2003, Published online: 23 May 2017
 

Abstract

Objective — Arterial restenosis after angioplasty limits long-term survival of patients. Murine arterial injury models develop neointimal hyperplasia similar to that observed in clinical coronary arterial restenosis after angioplasty. Adhesion of vascular cell adhesion molecule (VCAM)-1 and its ligand very late antigen (VLA)-4 plays an important role in neointimal formation after vascular injury.

Methods and results — To evaluate the effectiveness of blocking VCAM-1 and VLA-4 adhesion to prevent neointimal formation, mice with induced abdominal aortic injury were treated with the combined anti-VCAM-1 and anti-VLA-4 mAbs (n = 8) or not treated (n = 6). Injured arteries were harvested at day 14. Immunohistochemistry and in situ reverse transcriptase polymerase chain reaction were performed for detection of VCAM-1, intercellular adhesion molecule (ICAM)-1 and plateletderived growth factor (PDGF)-B mRNA expression in the arteries. Arteries without treatment showed significant neointimal formation with enhancement of ICAM-1, VCAM-1 and PDGF-B mRNA, while expression of these and intimal thickening were almost nonexistent in the recipients of mAbs to VCAM-1 and VLA-4.

Conclusion — Anti-VCAM-1 and anti-VLA-4 mAbs prevent arterial neointimal formation after arterial injury. (Acta Cardiol 2004; 59(2): 147-152

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.